Researchers demonstrated for the first time that a growth hormone-releasing hormone (GHRH) antagonist has anti-angiogenic properties, meaning it can inhibit the formation of new blood vessels. The antagonist MZ-4-71 both reduced the proliferation of endothelial cells and suppressed their production of VEGF, a key protein that drives new blood vessel growth. Since tumors depend on new blood vessels to grow and spread, this finding suggests an additional mechanism by which GHRH antagonists may fight cancer.
Siejka, A; Ławnicka, H; Komorowski, J; Schally, A V; Stepień, T; Krupiński, R; Stepień, H